Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers.

ABSTRACT: Despite inducing strong and durable clinical responses, targeted therapies do not eliminate advanced cancers, as a subset of tumor cells survives within residual tumors, eventually developing resistance. The ability of tumor cells to avoid therapeutic elimination can be mediated both by cell-intrinsic and microenvironmental mechanisms. Whilst the specific molecular mediators of cell-intrinsic and microenvironmental resistance are well understood, their relative contribution to in vivo therapeutic responses remains poorly defined. Using spatial histological inferences from experimental models of ALK+ NSCLC, we found that peristromal niches protected tumor cells from therapeutic elimination in vivo, enabling in vivo persistence. Whereas the development of bona fide resistance is assoc

SUBMITTER: Desai B 

PROVIDER: S-EPMC12045365 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature